Comparative Utility of Doxorubicin, Cyclophosphamide, and Docetaxel in Breast Cancer Treatment in West Sumatera.
Abstract
The large number of breast cancer cases in Indonesia and the high cost of treatment cause the need for utility analysis. West Sumatra province ranks second with the highest prevalence of breast cancer in Indonesia. This study aimed to determine the quality of life of breast cancer patients at the national referral hospital Dr. M. Djamil, West Sumatra, who underwent chemotherapy. This study used a cross-sectional design from January to April 2024. Data collection was done prospectively by filling out questionnaires at the Chemotherapy Unit. Utility value was obtained from filling out a questionnaire with the EQ-5D-5L instrument. Data were analyzed using the Mann-Whitney and Kruskal-Wallis tests. The data obtained was 47 respondents who received Doxorubicin and Cyclophosphamide chemotherapy regimen (24 respondents) and a Docetaxel chemotherapy regimen (23 respondents), all of whom met the inclusion criteria in this study. The average utility value obtained for the doxorubicin and cyclophosphamide regimes is 0.637, and the average utility value for the docetaxel regimen is 0.704. Age did not affect utility (p>0.05), while recent education, occupation, and patient origin affected utility (p<0.05). Both regimens provided similar perceived quality of life and overall health status as measured by utility and VAS scores, suggesting comparable patient-reported quality of life outcomes between these chemotherapy treatments.
Keywords
References
Adanu, K. K. et al. (2022) 'Household treatment cost of breast cancer and cost coping strategies from a tertiary facility in Ghana', PLOS Global Public Health, 2(3), p. e0000268. doi: 10.1371/journal.pgph.0000268.
Altun, İ. and Sonkaya, A. (2018) 'The most common side effects experienced by patients were receiving first cycle of chemotherapy', Iranian Journal of Public Health, 47(8), pp. 1218–1219.
Andayani, T. . (2013) Pharmacoeconomics: Principles & Methodology (Farmakoekonomi Prinsip & Metodologi). 1st edn. Yogyakarta: Bursa Ilmu.
Arora, A. et al. (2019) 'Cancer pain, anxiety, and depression in admitted patients at a tertiary care hospital: A prospective observational study', Indian Journal of Palliative Care, 25(4), pp. 562–566. doi: 10.4103/IJPC.IJPC_4_19.
Battisti, N. M. L. et al. (2021) 'Bridging the Age Gap in breast cancer: Impact of chemotherapy on quality of life in older women with early breast cancer.', European journal of cancer (Oxford, England : 1990), 144, pp. 269–280. doi: 10.1016/j.ejca.2020.11.022.
Binotto, M. et al. (2020) 'Health-related quality of life before and during chemotherapy in patients with early-stage breast cancer', Ecancermedicalscience, 14, pp. 1–11. doi: 10.3332/ECANCER.2020.1007.
Desriani et al. (2021) 'Design and characterization of a SYBR Green I-based melting curve method for investigation of HER2I655V polymorphism in breast cancer', Journal of Genetic Engineering and Biotechnology, 19(1), pp. 0–6. doi: 10.1186/s43141-020-00108-9.
Dipiro, J. et al. (2020) Pharmacotherapy : A Pathophysiologic Approach, 11th Edition. In Annals of Pharmacotherapy. 11th edn. McGraw-Hill Companies Inc.
Fitria, N. (2023) 'Pharmacoeconomic Analysis of the Use of Metformin and Glimepiride Combination'. Padang: Pustaka Egaliter.
Gautama, W. (2022) 'Breast Cancer in Indonesia in 2022: 30 Years of Marching in Place', Indonesian Journal of Cancer, 16(1), p. 1. doi: 10.33371/ijoc.v16i1.920.
Hernandez Alava, M. et al. (2018) 'EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom', Value in Health, 21(1), pp. 49–56. doi: 10.1016/j.jval.2017.09.004.
Kouwenberg, C. A. E. et al. (2019) 'The validity of the EQ-5D-5L in measuring quality of life benefits of breast reconstruction', Journal of Plastic, Reconstructive and Aesthetic Surgery, 72(1), pp. 52–61. doi: 10.1016/j.bjps.2018.08.023.
Leinert, E. et al. (2017) 'The impact of age on quality of life in breast cancer patients receiving adjuvant chemotherapy - A comparative analysis from the prospective multi-center randomized ADEBAR trial', Clinical Breast Cancer, 17(2), pp. 100–106. doi: 10.1016/j.clbc.2016.10.008.
de Ligt, K. M. et al. (2019) 'The impact of health symptoms on health-related quality of life in early-stage breast cancer survivors', Breast Cancer Research and Treatment, 178(3), pp. 703–711. doi: 10.1007/s10549-019-05433-3.
Ministry of Health, Republic of Indonesia (2017) 'Clinical Effectiveness Health Technology Assessment Guideline', p. 175.
Ministry of Health, Republic of Indonesia (2018) 'National Medical Service Guidelines for Breast Cancer Management'.
National Cancer Control Committee (2015) 'National Guidelines for Breast Cancer Management'. Jakarta: Ministry of Health, Republic of Indonesia. Available at: http://kanker.kemkes.go.id/guidelines/PNPKPayudara.pdf.
Ngo, N. T. N. et al. (2023) 'Health-related quality of life in breast cancer patients in low-and-middle-income countries in Asia: a systematic review', Frontiers in Global Women's Health, 4(June), pp. 1–9. doi: 10.3389/fgwh.2023.1180383.
Novianti, L. E., Wungu, E. and Purba, F. D. (2020) ‘Quality of Life as A Predictor of Happiness and Life Satisfaction’, Jurnal Psikologi, 47(2), p. 93. doi: 10.22146/jpsi.47634.
Saptaningsih, A. B. et al. (2022) 'Cost-Effectiveness Analysis of Two Chemotherapy Regiments FAC vs. Taxane for Operable Breast Cancer Patients in Indonesia.', Asian Pacific journal of cancer prevention : APJCP, 23(4), pp. 1147–1154. doi: 10.31557/APJCP.2022.23.4.1147.
West Sumatra Riskesdas (2018) Basic Health Research of
West Sumatra Province 2018, National Riskesdas Report 2018.
DOI: 10.15408/pbsj.v6i2.40914
Refbacks
- There are currently no refbacks.
